Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 609

1.

Cost effectiveness of COX 2 selective inhibitors and traditional NSAIDs alone or in combination with a proton pump inhibitor for people with osteoarthritis.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG; National Institute for Health and Clinical Excellence Osteoarthritis Guideline Development Group.

BMJ. 2009 Jul 14;339:b2538. doi: 10.1136/bmj.b2538.

3.

Value of information in the osteoarthritis setting: cost effectiveness of COX-2 selective inhibitors, traditional NSAIDs and proton pump inhibitors.

Latimer N, Lord J, Grant RL, O'Mahony R, Dickson J, Conaghan PG.

Pharmacoeconomics. 2011 Mar;29(3):225-37. doi: 10.2165/11584200-000000000-00000.

PMID:
21062104
4.

A comparison of the cost-effectiveness of five strategies for the prevention of non-steroidal anti-inflammatory drug-induced gastrointestinal toxicity: a systematic review with economic modelling.

Brown TJ, Hooper L, Elliott RA, Payne K, Webb R, Roberts C, Rostom A, Symmons D.

Health Technol Assess. 2006 Oct;10(38):iii-iv, xi-xiii, 1-183. Review.

5.

Systematic reviews of the clinical effectiveness and cost-effectiveness of proton pump inhibitors in acute upper gastrointestinal bleeding.

Leontiadis GI, Sreedharan A, Dorward S, Barton P, Delaney B, Howden CW, Orhewere M, Gisbert J, Sharma VK, Rostom A, Moayyedi P, Forman D.

Health Technol Assess. 2007 Dec;11(51):iii-iv, 1-164. Review.

6.
7.

Cost-utility of celecoxib use in different treatment strategies for osteoarthritis and rheumatoid arthritis from the Quebec healthcare system perspective.

Bessette L, Risebrough N, Mittmann N, Roussy JP, Ho J, Zlateva G.

J Med Econ. 2009 Sep;12(3):246-58. doi: 10.3111/13696990903288970.

PMID:
19743942
8.
9.

Economic evaluation of nonsteroidal anti-inflammatory drug strategies in rheumatoid arthritis.

Inotai A, Mészáros A.

Int J Technol Assess Health Care. 2009 Apr;25(2):190-5. doi: 10.1017/S0266462309090242.

PMID:
19366498
10.

The effectiveness of five strategies for the prevention of gastrointestinal toxicity induced by non-steroidal anti-inflammatory drugs: systematic review.

Hooper L, Brown TJ, Elliott R, Payne K, Roberts C, Symmons D.

BMJ. 2004 Oct 23;329(7472):948. Epub 2004 Oct 8. Review.

11.

Economic evaluation of etoricoxib versus non-selective NSAIDs in the treatment of osteoarthritis and rheumatoid arthritis patients in the UK.

Moore A, Phillips C, Hunsche E, Pellissier J, Crespi S.

Pharmacoeconomics. 2004;22(10):643-60.

PMID:
15244490
12.

Arthritis treatment in Hong Kong--cost analysis of celecoxib versus conventional NSAIDS, with or without gastroprotective agents.

You JH, Lee KK, Chan TY, Lau WH, Chan FK.

Aliment Pharmacol Ther. 2002 Dec;16(12):2089-96.

13.

Strategies to optimize treatment with NSAIDs in patients at risk for gastrointestinal and cardiovascular adverse events.

Scheiman JM, Hindley CE.

Clin Ther. 2010 Apr;32(4):667-77. doi: 10.1016/j.clinthera.2010.04.009. Review.

PMID:
20435236
14.

A cost-effectiveness analysis of celecoxib compared with diclofenac in the treatment of pain in osteoarthritis (OA) within the Swedish health system using an adaptation of the NICE OA model.

Brereton N, Pennington B, Ekelund M, Akehurst R.

J Med Econ. 2014 Sep;17(9):677-84. doi: 10.3111/13696998.2014.933111. Epub 2014 Jun 30.

PMID:
24914585
15.

Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis.

Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T.

J Med Assoc Thai. 2009 Dec;92 Suppl 6:S19-26.

PMID:
20128070
16.

Efficiency of naproxen/esomeprazole in association for osteoarthrosis treatment in Spain.

Capel M, Tornero J, Zamorano JL, Oyagüez I, Casado MÁ, Sánchez-Covisa J, Lanas A.

Reumatol Clin. 2014 Jul-Aug;10(4):210-7. doi: 10.1016/j.reuma.2013.11.009. Epub 2013 Dec 29. English, Spanish.

17.

Economic evaluation of celecoxib, a new cyclo-oxygenase 2 specific inhibitor, in Switzerland.

Chancellor JV, Hunsche E, de Cruz E, Sarasin FP.

Pharmacoeconomics. 2001;19 Suppl 1:59-75.

PMID:
11280106
18.

Cost-utility analysis of duloxetine in osteoarthritis: a US private payer perspective.

Wielage RC, Bansal M, Andrews JS, Klein RW, Happich M.

Appl Health Econ Health Policy. 2013 Jun;11(3):219-36. doi: 10.1007/s40258-013-0031-3.

PMID:
23616247
19.

Gastroprotective strategies in chronic NSAID users: a cost-effectiveness analysis comparing single-tablet formulations with individual components.

de Groot NL, Spiegel BM, van Haalen HG, de Wit NJ, Siersema PD, van Oijen MG.

Value Health. 2013 Jul-Aug;16(5):769-77. doi: 10.1016/j.jval.2013.05.002. Epub 2013 Jul 11.

Supplemental Content

Support Center